Jonathan A Copp
Overview
Explore the profile of Jonathan A Copp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
916
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rascoe A, Peng E, Ferrell D, Copp J, Liu R
Cureus
. 2024 Apr;
16(3):e56331.
PMID: 38628990
Purpose When treating limb length discrepancy (LLD), decisions regarding lengthening versus contralateral shortening require careful consideration of deformity and patient factors. Using the National Longitudinal Survey of Youth 1979 (NLSY79)...
2.
Tejwani N, Ostrum R, Wolinsky P, Adenikinju A, Radley J, Copp J, et al.
Instr Course Lect
. 2022 Mar;
71:285-301.
PMID: 35254789
Common fractures managed by orthopaedic surgeons include ankle fractures, proximal humerus fractures in patients older than 60 years, humeral shaft fractures, and distal radius fractures. Recent trends indicate that surgical...
3.
Tian X, Werner M, Roche K, Hanson A, Foote H, Yu S, et al.
Nat Biomed Eng
. 2019 Apr;
2(6):443-452.
PMID: 31011191
Metastatic disease remains the primary cause of mortality in cancer patients. Yet the number of available in vitro models to study metastasis is limited by challenges in the recapitulation of...
4.
Su C, Copp J, Weinberg D, Kraay M, Fitzgerald S, Wera G
J Knee Surg
. 2019 Mar;
33(6):603-610.
PMID: 30921820
Readmission within 90 days following total joint arthroplasty has become a central quality measure of reimbursement initiatives; however, the validity of readmission rates as a measure of hospital care quality...
5.
Luk B, Jiang Y, Copp J, Hu C, Krishnan N, Gao W, et al.
Mol Pharm
. 2018 Mar;
15(9):3723-3728.
PMID: 29533668
Within the body, cellular recognition is mediated in large part by receptor-ligand interactions that result from the surface marker expression of the participant cells. In the case of immune cells,...
6.
Luk B, Fang R, Hu C, Copp J, Thamphiwatana S, Dehaini D, et al.
Theranostics
. 2016 May;
6(7):1004-11.
PMID: 27217833
The therapeutic potential of nanoparticle-based drug carriers depends largely on their ability to evade the host immune system while delivering their cargo safely to the site of action. Of particular...
7.
Wang F, Gao W, Thamphiwatana S, Luk B, Angsantikul P, Zhang Q, et al.
Adv Mater
. 2015 May;
27(22):3437-43.
PMID: 25931231
No abstract available.
8.
Copp J, Fang R, Luk B, Hu C, Gao W, Zhang K, et al.
Proc Natl Acad Sci U S A
. 2014 Sep;
111(37):13481-6.
PMID: 25197051
Pathological antibodies have been demonstrated to play a key role in type II immune hypersensitivity reactions, resulting in the destruction of healthy tissues and leading to considerable morbidity for the...
9.
Fang R, Hu C, Luk B, Gao W, Copp J, Tai Y, et al.
Nano Lett
. 2014 Mar;
14(4):2181-8.
PMID: 24673373
Cell-derived nanoparticles have been garnering increased attention due to their ability to mimic many of the natural properties displayed by their source cells. This top-down engineering approach can be applied...
10.
Karve S, Werner M, Sukumar R, Cummings N, Copp J, Wang E, et al.
Proc Natl Acad Sci U S A
. 2012 May;
109(21):8230-5.
PMID: 22547809
One of the promises of nanoparticle (NP) carriers is the reformulation of promising therapeutics that have failed clinical development due to pharmacologic challenges. However, current nanomedicine research has been focused...